Advertisment

Amgen Tests New Dosing Strategy for Obesity Drug MariTide

author-image
Dr. Jessica Nelson
New Update
NULL

Amgen Tests New Dosing Strategy for Obesity Drug MariTide

Advertisment

Amgen's Obesity Drug Shows Potential

Advertisment

Amgen, a leading biotechnology company, is testing a novel strategy with its obesity drug candidate known as MariTide. The goal is to determine whether patients can be gradually transitioned to lower or less frequent doses of the drug over time. This development promises to offer new insights into the long-term efficacy and safety of the drug candidate for the treatment of obesity.

Early data from ongoing tests suggest that MariTide may provide longer-lasting weight loss than other popular obesity drugs currently available in the market. In the ongoing Phase 2 trial, Amgen's researchers aim to titrate participants up on MariTide and then observe if the drug can still be effective when transitioning patients to a less intensive dosing regimen.

MariTide: A Success in the Making?

Advertisment

Amgen's new weight-loss drug, MariTide, is showing signs of success and could potentially offer longer-lasting weight loss than its rivals. Early data indicate that the drug can wean patients to lower or less frequent doses. The drug showed a significant 14.5% average weight reduction over 85 days in a Phase I study. Animal and early-stage human trial data for Amgen's experimental obesity drug, published in a medical journal, showed that it promoted significant weight loss with an acceptable safety profile.

The data detailed outcomes and adverse events for the 49 patients in the Phase 1 trial of the drug. The drug also significantly lowered the blood pressure of adults with overweight or obesity who took it for nine months. These findings offer hope for a new and effective treatment strategy for obesity.

Comparative Efficacy of MariTide

Advertisment

Compared to other obesity drugs in the market, MariTide has shown great potential in offering longer-lasting weight loss effects. The drug, which activates the GLP-1 hormone and blocks the activity of the GIP hormone, led to a mean loss of 14.5% of body weight in the highest dose group. However, some patients dropped out of the study, and levels of blood sugar trended back towards baseline after the trial.

Despite these challenges, Amgen is committed to demonstrating the effectiveness of MariTide and is currently conducting a Phase 2 trial of the drug with results expected by the end of this year. The results of this trial will provide further insights into the drug's long-term benefits and safety profile.

Conclusion

The strategy of testing whether patients can be weaned toward lower or less frequent doses over time is an innovative approach in the treatment of obesity. If successful, it could revolutionize the way obesity is treated, leading to improved health outcomes for patients. As we await the results of Amgen's ongoing Phase 2 trials, the initial findings offer a ray of hope in the battle against obesity.

Advertisment
Chat with Dr. Medriva !